News

Treatment with the combination of idelalisib and ofatumumab demonstrated an improvement in objective response rates, progression-free survival, and lymph node response compared with ofatumumab alone in patients with previously treated chronic lymphocytic leukemia.

The oral selective small molecule HER2 inhibitor ONT-380 in combination with other therapies demonstrated promising activity in previously treated patients with HER2-positive metastatic breast cancer, including those with CNS metastases.

Neoadjuvant ado-trastuzumab emtansine demonstrated promising complete pathological response in patients with hormone receptor-positive and HER2-positive early stage breast cancer

Low expression of the genes ERCC1 and TS was associated with substantial improvements in overall survival following front-line treatment with an oxaliplatin-based chemotherapy regimen for patient with metastatic colorectal cancer.

Venetoclax has demonstrated promising efficacy and a tolerable safety profile as monotherapy and in combinations for patients with relapsed/refractory multiple myeloma

Treatment with ramucirumab did not demonstrate a statistically significant improvement in overall survival compared with placebo for patients with hepatocellular carcinoma who had received prior treatment with sorafenib.

Treatment with ibrutinib plus the anti-CD20 antibody ublituximab was shown to be safe with an objective response rate of 95% in patients with chronic lymphocytic leukemia.

Treatment with inotuzumab ozogamicin was found to be safe and effective in a phase III study for patients with relapsed or refractory acute lymphoblastic leukemia.

Treatment with panitumumab improved overall survival compared with best supportive care in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.

This case-based program is designed to educate healthcare providers on the optimal management of patients with ER+/HER2– MBC, with the goal of improving patient outcomes including quality of life and survival.

Treatment with the PD-1 inhibitor nivolumab demonstrated durable objective response rates in patients with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

The treatment of patients with metastatic melanoma has undergone a dramatic transformation since the approval of the CTLA-4 inhibitor ipilimumab in 2011.

CTL019 demonstrated intriguing antitumor activity in a small study of patients with refractory multiple myeloma.

Hand-foot skin reaction represents one of the most troublesome adverse events associated with the multikinase inhibitor regorafenib, yet most treating physicians are unfamiliar with management tactics for this debilitating side effect.

The IDH2 inhibitor AG-221 has demonstrated promising response rates in patients with acute myeloid leukemia and other hematologic malignancies.

Inhibition of the activin receptor-like kinase 1 (ALK1) protein may prevent metastasis of breast cancer, according to a study published in Cancer Research.

The combination of selective internal radiation therapy (SIRT) with first-line chemotherapy showed a 31% reduction in the risk of disease progression within the liver of patients with metastatic colorectal cancer (mCRC) compared with chemotherapy alone.

Researchers at the Wistar Institute Cancer Center have discovered a new potential circulating biomarker for non–small cell lung cancer. It is a cancer testis antigen expressed by a cancer/testis gene called AKAP4. The exciting prospect this heralds is the development of an accurate, quick blood test for early-stage NSCLC.

A team at Weill Cornell Medical College in New York that is studying ovarian cancer has not only discovered another mechanism by which tumors evade attack by the immune system, but is also devising a first-in-class potential treatment.

The next-generation ALK inhibitor alectinib has demonstrated robust objective response rates (ORR) in patients with ALK-positive non–small cell lung cancer, including those with central nervous system metastases.

The glycoprotein CD31 was associated with improvements in overall survival and progression-free survival for patients with advanced ovarian cancer treated with frontline bevacizumab.

Rucaparib showed an overall response rate of 82% among a cohort of patients with BRCA-mutated ovarian cancer in the phase II ARIEL2 study.

The FDA has granted a priority review to pembrolizumab as a potential treatment for patients with advanced non-small cell lung cancer following treatment with chemotherapy or a targeted therapy, if applicable.

The House of Representatives Energy and Commerce Committee unanimously approved the 21st Century Cures Act in a 51-0 vote that took place last week.

The vortex fluidic device, invented by Colin Raston FRACI CChem FRSC, is capable of “uncooking” an egg, but latest research demonstrates it can also manufacture new targeted cancer therapies at lower costs.

Treatment with the PD-1 inhibitor nivolumab demonstrated similar efficacy regardless of prior treatment with a BRAF inhibitor or ipilimumab in patients with BRAF mutant or wild type metastatic melanoma.

Optimal outcomes, and perhaps even a cure, could be achieved with the combination of targeted therapies and immune checkpoint inhibitors.

A study published in the Journal of Clinical Oncology, May 18, 2015, details payer cost and use, as well as out-of-pocket (OOP) spending, for privately insured nonelderly patients receiving oral or intravenous (IV) chemotherapy for the treatment of cancer.

Joyce A. O’Shaughnessy, MD, chair, breast cancer service at Baylor-Sammons Cancer Center provided Targeted Oncology with a sneak peek into some of the recent advances in breast cancer that will be discussed at the 14th Annual International Congress on the Future of Breast Cancer®

TAS-102 (tipiracil hydrochloride) improved overall survival (OS) compared with placebo for patients with refractory metastatic colorectal cancer (CRC).